Startup nPharmakon turns drug development upside down

10/3/2012 | MedCityNews.com

Biotech firm nPharmakon has developed a platform that analyzes molecules for their effect on diseases, rather than identifying a specific disease target. The program retargets molecules whose safety has been proven but which have not proved effective against the target disease. nPharmakon works with drugmakers and has found new targets for about 12 drugs.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC